![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 48, 46544-46551, November 29, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, December 6, 2001, and in revised form, August 9, 2002
A mammalian basic helix-loop-helix protein known
variably as Stra13, Sharp2, and Dec1 has been implicated in cell
activation, proliferation, and differentiation. Indeed,
Stra13 null mice develop age-induced autoimmunity as a
result of impaired T-lymphocyte activation, leading ultimately to the
accumulation of autoreactive T-cells and B-cells. Stra13 is expressed
in embryonic as well as adult tissues derived from
neuroectoderm, mesoderm, and endoderm and has been associated with
response to hypoxia, suggesting a complex role for this protein and the
highly related Sharp1/Dec2 protein in homeostatic regulation. Whereas
Stra13 is known to regulate many important cellular functions
and is known to cross-regulate biological responses to other basic
helix-loop-helix containing transcription factors, including c-Myc and
USF, it is unclear if this protein binds directly to DNA. Indeed, the
basic domain of Stra13 contains a proline residue at an unprecedented
position. Herein, we have determined that Stra13 binds with high
affinity to CACGTG class B E-box elements as a homodimer with
preference for elements preceded by T and/or followed by A residues. In
addition, transient transfection experiments reveal that Stra13
represses transcription when bound to these and related sites. Our data suggest that Stra13 regulates cellular functions through antagonism of
E-box activator proteins and also through active repression from E-box elements.
Basic helix-loop-helix proteins represent a large and diverse
class of transcription factors implicated in cell fate specification, cell proliferation, apoptosis, metabolism, and cell activation (1). The
Stra13, Sharp2, Dec1 basic helix-loop-helix transcription factor has
been identified in a number of biological contexts (for simplicity we
will refer to this protein as Stra13). For example, Stra13
was identified as a retinoic acid-inducible gene that promotes neuronal
differentiation in P19 embryonal carcinoma cells (2). In addition,
Stra13 and a related protein, Sharp1/Dec2, were identified in a
degenerate PCR screen for
bHLH1 proteins expressed in
the adult rat brain (3). Interestingly, Stra13 and
Sharp1/Dec2 were both induced as immediate early
genes in cultured PC12 pheochromocytoma cells treated with nerve growth factor, and Stra13 was rapidly induced by glutamatergic
stimulation throughout the rat cerebral cortex (3). This gene was also identified as a cAMP-inducible transcript in differentiating
chondrocytes (4) and was later found to be cAMP-inducible in many cell
types (5). More recent work has described Stra13 induction following T-cell activation (6), tyrosine kinase receptor signaling (7), hypoxia
(8-10), and even serum starvation (11). Taken together, these data
indicate that Stra13 expression is closely associated with activation
and stress in many cell types.
Recently, Sun et al. (6) have used gene targeting to
generate Stra13 Cell Culture--
COS-7 cells were maintained in
Iscove's medium supplemented with 10% fetal bovine serum, whereas
HC11 cells were maintained in RPMI 1640 supplemented with epidermal
growth factor (10 ng/ml), insulin (5 µg/ml), and 10% fetal bovine
serum (13, 14).
Transfections--
For transfections, HC11 or COS-7 cells were
seeded at a dilution of 1:20 (60-mm plates) or 1:30 (6-well plates) in
their respective media. Transfections were carried out using the
Superfect (Qiagen) transfection reagent according to manufacturer's
specifications. Typically, for 60-mm cell cultures 4-6 and 10-12 µg
of total DNA were used for COS-7 and HC11 cells, respectively. Cells
were lysed 36-48 h post-transfection using ice-cold 1× Triton X-100
lysis buffer (50 mM Hepes, pH 7.4, 150 mM NaCl,
10% glycerol, 1% Triton X-100, 1 mM EGTA, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin, and
10 mM NaF). Soluble and insoluble fractions were separated
by centrifugation at 13,200 rpm for 15 min at 4 °C. Soluble protein
was then used to perform luciferase/ Plasmid Vectors--
Murine Stra13 was cloned from
mammary gland cDNA through a combination of reverse transcriptase
PCR and high stringency hybridization based on the identification of an
expressed sequence tag sequence, which at the time represented a
fragment from a novel bHLH domain containing
cDNA.2 The
Stra13 constructs described in the following section were subcloned into pcDNA3 for expression in transfected COS-7 and HC11
cells (Invitrogen). FLAG-Stra13 and
Stra13-Myc were created using PCR to add an in-frame epitope
tag at the N- and C-terminal ends, respectively, of the
Stra13 open reading frame. The FLAG epitope tag is DYKDDDDK,
which is recognized by the M2 monoclonal antibody (Sigma), whereas the
Myc epitope tag is EQKLISEED, and is recognized by the 9E10 monoclonal
and A-14 rabbit polyclonal antibodies (Santa Cruz Biotechnology).
The Stra13 C-terminal deletion mutants were created using
pBSK-FLAG-Stra13 as a substrate for exonuclease III
(Exo-Size deletion kit, New England Biolabs). For this purpose, a
double-stranded oligonucleotide was inserted downstream of the
Stra13 stop codon. It contained a unique HindIII
restriction site (exonuclease III-sensitive restriction site), a unique
SpI restriction site (exonuclease III-resistant restriction site), and
three frame stop codons. The precise extent of each deletion was
determined by nucleotide sequencing analysis. Based on their
distribution, particular deletion mutants were selected for further studies.
The epitope-tagged Stra13 basic domain mutant FLAG-Stra13( Binding Site Selection and EMSA Assays--
The PCR-based site
selection protocol was performed as previously described (16). For
electrophoretic mobility shift assays (EMSA), 5 µg of each
complementary single-stranded oligonucleotide were annealed in a final
volume of 50 µl of 50 mM Tris-HCl (pH 8), 10 mM MgCl2, 50 mM NaCl. 0.4 µg of
annealed oligonucleotides was labeled with
[32P]dCTP for 1 h at room temperature with Klenow
(Invitrogen), separated from free nucleotides by passage through
NICK columns (Amersham Biosciences), and eluted into 300 µl of
Tris/EDTA for a probe concentration of 1.3 ng/µl. Cold competitors
(40 ng/µl) were prepared in the same manner using Klenow and
non-radioactive dNTPs. Proteins were synthesized using 1 µg of
linearized DNA template in the TNT Quick
transcription/translation kit (Promega) according to manufacturer's
specifications. Protein-DNA complexes were formed by incubation of
protein (4 µl from a 50-µl reaction) with 2.5 ng of radiolabeled
double-stranded oligonucleotide in a final volume of 20 µl (10 mM Tris, pH 8, 40 mM KCl, 6% glycerol, 1 mM dithiothreitol, 0.05% Nonidet P-40) with a total of 500 ng of poly(dI/dC), 2 µg of BSA, and 0.1 µg of salmon sperm DNA.
Binding reactions were performed at room temperature for 20 min. For
supershift experiments, 1 µg of mouse anti-FLAG monoclonal antibody
(Sigma) was added to binding reactions. DNA-protein complexes were
resolved by electrophoresis on 5% acrylamide gel, after which gels
were dried and exposed to BioMax film with an intensifying
screen at Immunoprecipitation/Western
Blotting--
1 µg of primary antibody was added to soluble protein
lysates and incubated at 4 °C for 1 h (COS-7 lysates) or
overnight (HC11 lysates). Secondary goat anti-mouse IgG coupled
to agarose beads (Sigma catalog no. A-6531) was added to the
immunoprecipitation reaction, which was then incubated for an
additional 30 min at 4 °C. Beads were washed six times using 1×
Triton X-100 lysis buffer (without protease or phosphatase inhibitors)
and resuspended by boiling in sample buffer containing 40 mM dithiothreitol. The resulting denatured protein samples
were first separated electrophoretically on SDS-PAGE gels and then
transferred onto nitrocellulose membranes. Western blots were blocked
in 5% BLOTTO (10 mM Tris, pH 7.5, 150 mM NaCl,
0.05% (v/v) Tween 20, and 5% (w/v) skim milk powder) and then probed
with the appropriate primary rabbit polyclonal antibody (0.5 µg/ml)
in 1% BLOTTO for 1 h. The membranes were then rinsed (4 × 15 min) in 1% BLOTTO followed by incubation with peroxidase-conjugated
goat anti-rabbit (Jackson ImmunoResearch Laboratories) at a dilution of
1:104 for 1 h in 1% BLOTTO. Finally, the membranes
were rinsed with 1% BLOTTO (4 × 15 min) followed by
immunodetection using Amersham ECL Western blotting detection reagents
according to the manufacturer's guidelines.
Luciferase/ Immunofluorescence--
HC11 or COS-7 cells were seeded on cover
slips, transfected, and 24 h later rinsed with phosphate-buffered
saline (PBS), fixed in ice-cold methanol (30 min), and washed in PBS
(3 × 10 min). Cells were then blocked in 1% BSA/PBS for 1 h
and incubated for 1 h with Stra13 Homodimerizes in Vivo--
In a screen to clone
bHLH-encoding genes expressed in the mouse mammary gland, we identified
a cDNA that was subsequently identified in a number of tissues and
cell lines.2 This gene, Stra13, represents the
founding member of a novel family of genes encoding bHLH proteins with
an unusual basic domain sequence (2-4, 17). bHLH proteins typically
form homodimers and/or heterodimers in order to bind DNA target
elements (1). In vitro, Stra13 has previously been shown to
form homodimers and heterodimers with other bHLH proteins, including
E47 and Mash1 (2, 17). To test whether Stra13 forms homodimers in
vivo, we transfected COS-7 cells with two different epitope-tagged
versions of Stra13 (Fig. 1A).
In lysates from cells cotransfected with Myc epitope-tagged Stra13 and
FLAG epitope-tagged Stra13, anti-FLAG immunoprecipitates contained
Myc-tagged Stra13. In control lysates from cells singly transfected
with Myc-tagged Stra13, anti-FLAG antibodies could not
immunoprecipitate Myc-tagged Stra13. These data reveal that Stra13
homodimerizes in transfected COS-7 cells. Since HLH domains are
typically responsible for dimerization of bHLH transcription factors,
we tested if an N-terminal fragment of Stra13 (FLAG-Stra13-(1-143))
containing little more than the bHLH domain was sufficient for
homodimerization. As expected anti-FLAG antibodies immunoprecipitated
Myc-tagged Stra13 from lysates of cells cotransfected with
FLAG-Stra13-(1-143) and Stra13-Myc but not from lysates of cells
transfected with either cDNA alone (Fig. 1B). Next, we
tested whether the basic portion of the bHLH domain was necessary for
homodimerization by removing it or by replacing it with an acidic
domain (15). Basic domain deleted and acidic HLH variant Stra13
proteins were both able to dimerize with wild type Myc-tagged Stra13
(Fig. 1C). Finally, we determined the subcellular localization of FLAG-tagged wild type Stra13, FLAG-tagged
Stra13-(1-143), FLAG-tagged Stra13 Stra13 Homodimers Bind to the Class B E-box, CACGTG--
Most bHLH
proteins recognize short DNA elements that are related to the E-box
CANNTG. However, as Stra13 contains a proline residue at an unusual
position in its basic domain, it is not clear whether this protein
binds directly to DNA. We used a PCR-based binding site selection
protocol to test for a Stra13 homodimer binding site in
vitro (16). Because the bHLH domain of Stra13 is related to
enhancer of split family (E(Spl))/Hes bHLH domains and these proteins
were previously shown to bind N-box elements (CANNAG) (18, 19), we
first established very low stringency conditions under which in
vitro translated Stra13 could bind to N-box elements (specifically
CACGAG). This occurred in the absence of BSA and
poly(dI/dC) nonspecific competitors. This low affinity Stra13 N-box
complex was used as a molecular weight marker to purify specific Stra13
complexes from EMSA gels in the early rounds of our site selection
protocol. After three rounds of Stra13 binding, EMSA gel purification
of bound oligonucleotides, and PCR amplification we had enriched high
affinity Stra13-binding sites to a level where we would detect
radioactive Stra13-DNA complexes on the EMSA gel. The Stra13-bound DNA
pool was amplified by PCR, cloned, and sequenced (16). This revealed
enrichment for one type of 6-nucleotide site in 23 of 26 clones that
contained the predicted 70-bp insert (Table
I). Interestingly, the Stra13 binding
site identified in our screen was CACGTG, which is a class B E-box element (20). In addition, the CACGTG sequence was frequently preceded by a T residue and followed by an A residue, although these
are not absolutely required for high affinity binding (see below).
To test for the importance of individual bases on Stra13 binding to the
E-box identified in our screen, we performed EMSA assays to test for
binding to tCACGTGc sites (probe 2) under high stringency conditions in
the presence of BSA and poly(dI/dC) (Fig. 2A) (21). This element bound a
protein or proteins present in the control in vitro
transcription/translation reaction. However, when the in
vitro transcription/translation reaction was programmed with a
Stra13-FLAG epitope-tagged cDNA and this was incubated with probe
2, a novel Stra13-containing complex was formed that could be
supershifted through inclusion of anti-FLAG monoclonal antibody. The
anti-FLAG antibody did not supershift control complexes. We next tested
for formation of Stra13 complexes on related sites. For example, we
determined whether Stra13 bound to tCAGGTGa and gCAGGTGc to test for the importance of residues within the
selected E-box consensus and for the importance of flanking T and A
residues that were selected in our screen. Interestingly, Stra13 formed a specific complex with tCAGGTGa as determined by the
supershift of this complex in the presence of anti-FLAG antibody in the
binding reaction. This site has a single mutation in the core E-box but with optimal flanking residues. In contrast, Stra13 did not form complexes with gCAGGTGc, which has the same E-box core
mutation but without flanking T and A nucleotides. Next, we studied
Stra13-DNA interactions by testing whether various E-box elements could
compete Stra13 off of probe 2, tCACGTGc. Unlabeled excess tCACGTGc
(probe 2), tCACGTGa (probe 1, not shown), gCACGTGc (probe B1, not
shown), and gCACGTGt (probe B2, not shown) diminished radioactive
Stra13-probe 2 complex formation (Fig. 2B and data not
shown). Interestingly, excess unlabeled CAGGTG elements
including tCAGGTGa (mutant probe M1), gCAGGTGc
(probe A1), and gCAGGTGg (probe A2) did not compete Stra13
from labeled probe 2 (Fig. 2B and data not shown). In
addition, the single mutant gCACGCGa element (hairy probe)
(data not shown) and mutant E-box elements that differ from the CACGTG
consensus by 2 nucleotides could not compete with probe 2 for binding
to Stra13 (Fig. 2B and data not shown). Thus, Stra13 binds
with high affinity to CACGTG elements. It can also bind to single
mutant CAGGTG elements, although only when these elements
are surrounded by optimal flanking residues (Fig. 2A) and
only with significantly lower affinity than CACGTG elements (this
element did not compete for Stra13 binding in Fig. 2B).
Stra13 Is a Transcriptional Repressor of Class B E-box
Elements--
In previous work, GAL4-Stra13 fusion proteins were
shown to repress transcription from upstream activator
sequence elements that bind GAL4 (2). To determine whether Stra13
activates or represses transcription from its cognate DNA target site,
three copies of the tCACGTGa element were inserted upstream of the
minimal and thymidine kinase promoters in the luciferase vectors pGL3 and pGL3-TK, respectively. These constructs were transfected into COS-7
cells that do not express detectable Stra13 protein and also into HC11,
a mouse mammary epithelial line that expresses endogenous
Stra13.2 The addition of E-box elements dramatically
increased the luciferase activity generated by these vectors in both
lines (Fig. 3, A
and C), presumably because of the expression and effect of
endogenous E-box-binding transcription-activating proteins.
Cotransfection of FLAG-Stra13 repressed expression of either
promoter in a dose-dependent fashion (Fig. 3, A
and C). Interestingly, the N-terminal
FLAG-Stra13-(1-143) bHLH domain construct was as active as
full-length Stra13 in repressing transcription in these
assays, suggesting that repression was occurring as a result of Stra13
proteins competing with endogenous E-box activator proteins for access
to CACGTG elements (Fig. 3, A and C). To confirm
that repression by Stra13 involved competition with endogenous E-box
binding transcription factors for target CACGTG elements, we tested
whether FLAG-Stra13(
We next tested whether Stra13 could actively repress transcription in
the context of a complex promoter. Insertion of two copies of the
tCACGTGa element upstream of the SV40 promoter in the pGL3-SV40
luciferase vector did not affect gene expression in COS cells (Fig.
4A). Co-transfected
Stra13 inhibited transcription of this CACGTG-containing
promoter in a dose-dependent manner but did not repress the
parental pGL3-SV40 reporter (Fig. 4A). To test whether
specific E-box elements were required for Stra13-mediated transcriptional repression we inserted three Stra13 mutant binding sites, tCAGGTGa, tCATATGa, and
tCACGGAa, into the pGL3-SV40 reporter. Interestingly, the
single nucleotide mutant site tCAGGTGa was still
Stra13-responsive (Fig. 4B), consistent with the fact that tCAGGTGa elements bound Stra13 in vitro (Fig.
2A). In contrast, the double nucleotide mutant elements
tCATATGa and tCACGGAa that did not bind Stra13
in vitro were not responsive to Stra13 in vivo.
Repression from E-box elements required an intact basic domain in
Stra13, because it was not observed when
FLAG-Stra13(
Stra13 is a bHLH protein associated with cell activation and stress in
many tissues. Indeed, this protein is induced in activated neuronal
cells, chondrocytes, T-cells, fibroblasts, and a number of cancer cell
lines. Recent genetic analysis has revealed that Stra13 is required for
T-cell activation and regulation of lymphocyte clearance
(6). In addition, Stra13 has recently been implicated in
hypoxia-induced repression of adipogenesis (22). Despite the importance
of Stra13 in these biological processes, the biochemical mechanism by
which it functions remains unknown. For example, it had yet to be
determined whether Stra13, which includes a conserved proline residue
at an unprecedented site within its basic domain, binds directly to
DNA. We have used a non-biased screen to determine that Stra13 binds to
a specific DNA element, the CACGTG class B E-box element, with
preference for sites preceded by T and followed by A. Following
submission of this work, Zawel et al. (23) have recently
reported that human Stra13 binds CACGTG elements in vitro and can repress transcription from reporters containing these sites.
Such sites regulate expression of many genes associated with
proliferation, differentiation, and cell activation. We have also
determined that Stra13 can actively repress transcription of promoters
that contain class B E-box elements. The domain of Stra13 responsible
for transcriptional repression from CACGTG elements maps to sequences
in the N-terminal 333 amino acids of Stra13. This result is consistent
with data from Boudjelal et al. (2) who used GAL4-Stra13
chimeras to repress transcription from upstream activator sequence
sites and to map a repression domain between amino acids 147 and 354. In addition, Sun and Taneja (11) have determined that HDAC1 and
NcoR bind to Stra13 sequences between amino acids 111 and 343. Interestingly, the Stra13 deletion mutant Stra13-(1-322) that failed
to repress transcription (Fig. 4) still bound HDAC1, suggesting that
Stra13 may mediate transcriptional repression via multiple mechanisms
(data not shown).
These results are important given that Stra13 binds to and antagonizes
USF proteins (24) and represses expression of c-Myc (11), two classes
of bHLH-ZIP transcription activating proteins that bind to
CACGTG E-box elements. Stra13 also represses expression of its own
promoter through a mechanism requiring histone deacetylase activity
(11). Interestingly, the Stra13 promoter contains three CACGTG elements located 261, 1125, and 2901 bases upstream of the first
transcribed nucleotide (25). Recent work has identified the
PPAR We thank Brenda Cohen, Robert Phillips, Janet
Rossant, Mike Moran, Jay Cross, Howard Lipshitz, Zhe Jiang, Paul Hamel,
Jose Luis de la Pompa, Reshma Taneja, Wei Wang, Vivette Brown, and members of the Egan and Zacksenhaus laboratories for valuable discussion, encouragement, and support.
*
This work was supported by a grant from the Canadian
Institutes for Health Research (CIHR)/Apotex Inc. and the National
Cancer Institute of Canada (to S. E. E.) and a grant from the
National Cancer Institute of Canada (to E. Z.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Present address: Division of Cell and Molecular Biology, Toronto
General Research Institute-University Health Network, 67 College St.,
Toronto, Ontario M5G 2M1, Canada.
¶
Recipient of a CIHR studentship.
**
Recipient of a Conseil de la Recherche en Sciences (CRS)/CIHR scholarship.
Published, JBC Papers in Press, September 23, 2002, DOI 10.1074/jbc.M111652200
2
B. St-Pierre and S. E. Egan, unpublished data.
The abbreviations used are:
bHLH, basic
helix-loop-helix;
EMSA, electrophoretic mobility shift assay;
BSA, bovine serum albumin;
wt, wild type;
PBS, phosphate-buffered
saline.
Stra13 Homodimers Repress Transcription through Class B E-box
Elements*
§¶,
,
**, and

Programs in Cancer Research and
Developmental Biology, The Hospital for Sick Children,
Toronto, Ontario M5G-1X8, Canada, the Department of Molecular and
Medical Genetics, University of Toronto,
Toronto, Ontario M5G 2M1, Canada, and the
Department of
Medicine, Department of Laboratory Medicine and Pathobiology, and
Department of Medical Biophysics, University of Toronto, Division of
Cell and Molecular Biology, Toronto General Research
Institute-University Health Network,
Toronto, Ontario M5G 2M1, Canada
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
/
mice. Surprisingly,
homozygous Stra13 mutant mice are born and survive to
adulthood. However, aging Stra13 mutant mice develop an
autoimmune disorder. This effect has been traced to impaired CD4+
T-cell activation, with reduced interleukin-2 production, reduced clonal expansion, impaired T-cell differentiation, and reduced
clearance of activated lymphocytes (6). Despite indications that Stra13
may regulate activation and stress in a number of cell types,
Stra13-binding DNA elements have yet to be identified. Consequently,
the effect of this transcription factor on its theoretical DNA
target(s) is also unknown. The putative Stra13
DNA-binding/dimerization domain is somewhat related to bHLH
domains of enhancer of split family (E(spl))/Hes transcriptional
repressor proteins. However, Stra13 contains a proline residue in a
distinct location within the basic domain. Therefore it is not clear
whether Stra13 even binds directly to DNA. In addition, a fusion
construct between the GAL4 DNA-binding domain and Stra13 can repress
transcription from GAL upstream activator sequence sites through the
recruitment of a histone deacetylase and perhaps through direct effects
on the basal transcription factor TFIIB (2, 11). However, it is not
clear whether Stra13 functions as a DNA-binding repressor, a
co-repressor, or perhaps even a transcription activating protein that
is behaving inappropriately when fused to GAL4 (12). Indeed, the
conformation of a GAL4-Stra13 fusion protein on DNA would be
dramatically different from the conformation of Stra13 bound through
its own putative DNA-binding domain. Consequently, the biochemical
mechanism by which Stra13 functions remains unknown. Here we report
identification of the Stra13 DNA target site, the well described CACGTG
E-box element, with preference for this site preceded by T and/or
followed by an A residue. In addition we have determined that Stra13
can function as a homodimer to repress transcription from these sites.
These data identify Stra13 as a transcriptional repressor protein that
functions to regulate E-box elements through cross-interference with
E-box-binding transcriptional activators that bind such sites and
through direct transcriptional repression from the class B E-box and
related sites.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
-galactosidase assays and/or
immunoprecipitation/Western blotting experiments.
basic) was
created by linking through a chimeric XbaI site two PCR-generated Stra13 cDNA fragments corresponding,
respectively, to FLAG-tagged amino acids 1-49 and amino acids 67-136
of the Stra13 open reading frame. The resulting linked
mutant cDNA fragment in which the basic domain is specifically
deleted from the Stra13 sequence was used to replace the corresponding
wt N-terminal Stra13 sequence through fusion of the
basic N-terminal
fragment with the Stra13 C terminus using an internal XhoI.
FLAG-Stra13(acidic) was created by inserting a double-stranded
oligonucleotide coding for an in-frame peptide rich in acidic residues
(EEEDDEEE, see Krylov et al. (15)) in the unique
XbaI site of FLAG-Stra13(
basic). For
luciferase reporter vectors pGL3-(tCACGTGa)3 and
pGL3-(tCACGTGa)2-SV40, oligonucleotide probe 1 (see below)
was inserted at a unique NheI site of the Promega pGL3 and
pGL3-SV40 vectors. The sequence of pGL3-(tCACGTGa)3 from
SacI to XhoI is as follows:
GAGCTCTTACGCGTGCTAGCAATCCTTGTGTCACGTGACGTCTAGCAATCCTTGTGTCACGTGACACAAGGATTGCTAGCAATCCTTGTGTCACGTGACGTCTAGCCCGGGCTCGAG. The sequence of pGL3-(tCACGTGa)2-SV40 from SacI
to XhoI is as follows:
GAGCTCTTACGCGTGCTAGCAATCCTTGTGTCACGTGACACAAGGATTGCTAGACGTCACGTGACACAAGGATTGCTAGCCCGGGCTCGAG. Mutated E-box versions of
pGL3-(tCACGTGa)2-SV40 (i.e.
pGL3-(tCAGGTGa)2-SV40, pGL3-(tCATATGa)2-SV40, and
pGL3-(tCACGGAa)2-SV40) were created by
double-stranded oligonucleotide replacement of the
SacI-XhoI fragment of the multiple cloning site
of pGL3-SV40. The oligonucleotides were designed to identically
reproduce the sequence of pGL3-(tCACGTGa)2-SV40 except for
the mutated nucleotides at the designated positions of the two E-boxes.
pGL3-(tCACGTGa)3-TK was created by subcloning the thymidine
kinase promoter into the blunt-ended HindIII site of
pGL3-(tCACGTGa)3.
70 °C. Double-stranded oligo probe 2 (CTAGACGTCACGTGCCACAAGGATTGCTAG), probe M1
(CTAGACGTCAGGTGACACAAGGATTGCTAG with optimal flanking residues), probe A1
(CTAGTTGGCAGGTGCCAAAAGGATTGCTAG without flanking
T and A residues), and probe M2
(CTAGACGTCATATGACACAAGGATTGCTAG) were used for Fig. 2. In data not shown oligo probe 1 (CTAGACGTCACGTGACACAAGGATTGCTAG) was
found to bind Stra13 with equal if not higher affinity compared with
oligo probe 2. Additional probes with multiple mutations in the CACGTG
consensus did not bind Stra13 homodimers nor did they compete Stra13
off of probe 2 (data not shown).
-Galactosidase Assays--
For experiments shown
in Figs. 3 and 4, COS-7 cells or HC11 cells were transfected with 100 ng (Fig. 3, A-D), 25 ng (Fig. 3E), or 50 ng
(Fig. 4) of luciferase reporter vector along with increasing amounts of
pcDNA3 vector expressing either wt or mutant Stra13. In each case
the observed luciferase activity for each transfected sample was
corrected according to the
-galactosidase activity generated from a
co-transfected Rous sarcoma virus- or cytomegalovirus-lacZ vector.
The average corrected luciferase activity and standard deviation
of the duplicate samples for each test condition were plotted. The
average activity observed in the absence of co-transfected
Stra13-expressing construct was given a relative value of 100%. For
each experiment, levels of ectopic Stra13 protein were determined
through immunoprecipitation/Western blot analysis on duplicate samples
transfected with 4 µg (COS-7) or 10 µg (HC11) of Stra13 expression
vector. Each experiment shown was a representative of at least three
independent results. To determine the luciferase activity of each
sample, 10 µl of soluble protein lysate was mixed with 25 µl of
Promega luciferase reagent, and the light-emitting activity of the
sample was immediately determined for 20 s using a Berthoid Lumat
LB9501 luminometer. To determine the
-galactosidase activity from a
sample, 20 µl of soluble protein lysate was mixed with 200 µl of
reaction buffer (400 µg/ml
o-nitrophenyl-
-D-galactopyranoside, 0.1 M
NaPO4 (pH 7.5), 10 mM KCl, 1 mM
MgCl2, and 50 mM
-mercaptoethanol). Color development was allowed to proceed for 15-60 min at 37 °C and was
quantified using a SpectraMax250 Elisa plate reader (Molecular Devices).
-FLAG M2-fluorescein isothiocyanate
conjugate (Sigma F-4049) at a 1:20 dilution in 1% BSA/PBS. Coverslips
were then rinsed with PBS (3 × 10 min) and then mounted using
Dako® fluorescent mounting medium.
![]()
RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
basic, and the FLAG-tagged Stra13
acidic variants in transfected COS-7 cells and HC11 mouse mammary
epithelial cells. In each case Stra13 protein was found in the nucleus
(Fig. 1D).

View larger version (28K):
[in a new window]
Fig. 1.
Homodimerization and subcellular localization
of Stra13. A, COS-7 cells were transfected with
expression vectors for Stra13-Myc, FLAG-Stra13, or both as indicated.
Murine
-Myc (M) or
-FLAG (F) antibodies
were used to immunoprecipitate exogenous Stra13 protein. Each
immunoprecipitate was then analyzed by Western-blot analysis using
rabbit
-Stra13 or rabbit
-Myc antibodies. The N-terminal HLH
domain, but not the basic domain, was required for Stra13 homodimeric
interaction as revealed in cotransfection experiments with
Stra13-Myc and (B)
FLAG-Stra13-(1-143) or (C)
FLAG-Stra13(
basic) or FLAG-Stra13(acidic)
expression vectors. IP, immunoprecipitates. W,
Western. D, each Stra13 protein derivative is localized to
the nucleus in transfected COS-7 or HC11 cells. Immunostaining
was performed using fluorescein isothiocyanate-conjugated
-FLAG M2
antibodies.
Consensus sequences binding to Stra13 homodimers

View larger version (74K):
[in a new window]
Fig. 2.
Stra13 binds to CACGTG E-box elements.
A, electrophoretic mobility shift assay using radiolabeled
tCACGTGc-, tCAGGTGa-, or gCAGGTGc-containing
probes in the presence or absence of FLAG-Stra13 protein. The formation
of specific FLAG-Stra13-DNA complexes was confirmed by supershifting of
complexes in the presence of anti-FLAG antibody (indicated with an *).
B, the affinity of FLAG-Stra13 for tCACGTGc elements was
tested by competition using excess non-radiolabeled tCACGTGc,
tCAGGTGa, gCAGGTGc, or tCATATGa
sequences as indicated.
basic) and FLAG-Stra13(acidic) mutants could function as repressors in this system. Both
basic domain mutants were completely unable to repress transcription from the CACGTG elements at concentrations where wild type Stra13 inhibited transcription by ~90% (2 µg) (Fig. 3, B and
D). This effect was associated with disruption of DNA
binding as both proteins were stable (Fig. 1C) and found in
the nucleus (Fig. 1D). To test whether the basic domain
mutant proteins could function to sequester wild type Stra13 away from
E-box elements, we cotransfected Stra13 together with
FLAG-Stra13(
basic) or FLAG-Stra13(acidic). The repressor function of wild type Stra13 was blocked by
coexpression of either of these dimerization-competent mutant proteins
(Fig. 3E).

View larger version (27K):
[in a new window]
Fig. 3.
Competitive repression by Stra13 through
class B (CACGTG) E-box elements. COS-7 cells (A,
B, and E) or HC11 cells (C and
D) were transfected with luciferase reporter vector along
with increasing amounts of a pcDNA3 vector expressing either
wt Stra13 or mutant Stra13, or both, as indicated. The observed
luciferase activity for each transfected sample was corrected according
to the
-galactosidase activity generated from a co-transfected lacZ
vector (see "Experimental Procedures"). E, COS-7 cells
were transfected with pGL3-(tCACGTGa)3 luciferase reporter
vector in the presence or absence of 0.1 µg of
pcDNA3-FLAG-Stra13 vector. To test the ability of the
Stra13 basic domain mutants to act as dominant negative alleles by relieving the repression induced by
ectopic expression of wt Stra13, increasing amounts of
pcDNA3-FLAG-Stra13(
basic) or
pcDNA3-FLAG-Stra13(acidic) were also cotransfected. For
all panels the levels of ectopic Stra13 protein are shown by
immunoprecipitation/Western blot analysis for duplicate samples
transfected with 4 µg (COS-7) or 10 µg (HC11)
of pcDNA-Stra13 expression constructs.
basic) or FLAG-Stra13(acidic)
mutants were co-transfected with pGL3-(tCACGTGa)2-SV40-Luc (Fig. 4C). In addition, this effect represented active
repression because in contrast to the competitive repression observed
on minimal promoters (Fig. 3) repression of the SV40 promoter required sequences in the C-terminal 268 residues of Stra13 (data not shown). To
define sequences in Stra13 responsible for active repression of the
SV40 promoter in this context, we generated and cotransfected a series
of C-terminal truncation mutants (Fig. 4, D and
E). The C-terminal boundary of the transcriptional
repression domain was mapped to lie between residues 322 and 333, because C-terminal truncation mutants including
FLAG-Stra13-(1-333) were potent repressors, whereas
FLAG-Stra13-(1-322) and smaller C-terminal truncation mutants had lost this activity (Fig. 4D). The inability of
FLAG-Stra13-(1-322) to repress transcription was not caused by
a lack of expression of this mutant protein (Fig. 4D).

View larger version (26K):
[in a new window]
Fig. 4.
E-box-dependent
active repression of the SV40 early promoter by Stra13 in COS-7
cells. A, luciferase expression was monitored in COS-7
cells transfected with pGL3-(tCACGTGa)2-SV40 or control
pGL3-SV40 luciferase reporter vector along with increasing amounts of
pcDNA3-FLAG-Stra13. B, luciferase expression
was monitored in COS-7 cells transfected with
pGL3-(tCACGTGa)2-SV40,
pGL3-(tCAGGTGa)2-SV40,
pGL3-(tCATATGa)2-SV40, or
pGL3-(tCACGGAa)2-SV40 along with increasing
amounts of pcDNA3-FLAG-Stra13. C, luciferase
expression was monitored in COS-7 cells transfected with
pGL3-(tCACGTGa)2-SV40 along with increasing amounts of
basic domain mutant expression vectors for FLAG-Stra13(
basic) or
FLAG-Stra13(acidic). D, luciferase expression was monitored
in COS-7 cells transfected with pGL3-(tCACGTGa)2-SV40
luciferase reporter vector along with increasing amounts of
Stra13 nested deletions as shown in panel E.
Levels of ectopic wt or mutant Stra13 protein were comparable as
determined through immunoprecipitation/Western blot analysis of
duplicate samples transfected with 4 µg of
pcDNA-Stra13 expression constructs. E, a
schematic representation of the Stra13 open reading frame
with C-terminal deletion mutants.
2 gene as a target of Stra13-mediated transcriptional repression during hypoxia-induced suppression of adipogenesis (22).
Interestingly, the promoter element that responds to Stra13-mediated repression contains binding sites for C/EBP bZIP proteins but no
obvious E-box elements like those identified in our study. In addition,
the bHLH domain of Stra13 was sufficient to repress expression of
PPAR
2. Perhaps Stra13 represses PPAR
2 expression and adipogenesis
through direct inhibition of C/EBP function. Future studies will
be necessary to resolve the mechanism by which Stra13 represses
expression of Stra13 and PPAR
2 promoters and to identify E-box elements in the genome that are subject to regulation by Stra13 and the Stra13-related protein, Sharp1/Dec2. Indeed, the
Stra13-binding/responsive E-box elements identified in this study are
likely to represent critical nodes in a competitive network of
activator and repressor proteins controlling cell activation, proliferation, and stress.
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES

Recipient of a CIHR scholarship. To whom correspondence should
be addressed. Tel.: 416-813-5267; Fax: 416-813-8883; E-mail: segan@sickkids.on.ca.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
1.
Massari, M. E.,
and Murre, C.
(2000)
Mol. Cell. Biol.
20,
429-440 2.
Boudjelal, M.,
Taneja, R.,
Matsubara, S.,
Bouillet, P.,
Dolle, P.,
and Chambon, P.
(1997)
Genes Dev.
11,
2052-2065 3.
Rossner, M. J.,
Dorr, J.,
Gass, P.,
Schwab, M. H.,
and Nave, K. A.
(1997)
Mol. Cell Neurosci.
9,
460-475[CrossRef][Medline]
[Order article via Infotrieve]
4.
Shen, M.,
Kawamoto, T.,
Yan, W.,
Nakamasu, K.,
Tamagami, M.,
Koyano, Y.,
Noshiro, M.,
and Kato, Y.
(1997)
Biochem. Biophys. Res. Commun.
236,
294-298[CrossRef][Medline]
[Order article via Infotrieve]
5.
Shen, M.,
Kawamoto, T.,
Teramoto, M.,
Makihira, S.,
Fujimoto, K.,
Yan, W.,
Noshiro, M.,
and Kato, Y.
(2001)
Eur. J. Cell Biol.
80,
329-334[CrossRef][Medline]
[Order article via Infotrieve]
6.
Sun, H., Lu, B., Li, R. Q.,
Flavell, R. A.,
and Taneja, R.
(2001)
Nat. Immunol.
2,
1040-1047[CrossRef][Medline]
[Order article via Infotrieve]
7.
Fambrough, D.,
McClure, K.,
Kazlauskas, A.,
and Lander, E. S.
(1999)
Cell
97,
727-741[CrossRef][Medline]
[Order article via Infotrieve]
8.
Wykoff, C. C.,
Pugh, C. W.,
Maxwell, P. H.,
Harris, A. L.,
and Ratcliffe, P. J.
(2000)
Oncogene
19,
6297-6305[CrossRef][Medline]
[Order article via Infotrieve]
9.
Ivanova, A. V.,
Ivanov, S. V.,
Danilkovitch-Miagkova, A.,
and Lerman, M. I.
(2001)
J. Biol. Chem.
276,
15306-15315 10.
Yoon, D. Y.,
Buchler, P.,
Saarikoski, S. T.,
Hines, O. J.,
Reber, H. A.,
and Hankinson, O.
(2001)
Biochem. Biophys. Res. Commun.
288,
882-886[CrossRef][Medline]
[Order article via Infotrieve]
11.
Sun, H.,
and Taneja, R.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
4058-4063 12.
Ruden, D. M., Ma, J., Li, Y.,
Wood, K.,
and Ptashne, M.
(1991)
Nature
350,
250-252[CrossRef][Medline]
[Order article via Infotrieve]
13.
Wartmann, M.,
Cella, N.,
Hofer, P.,
Groner, B.,
Liu, X.,
Hennighausen, L.,
and Hynes, N. E.
(1996)
J. Biol. Chem.
271,
31863-31868 14.
Ball, R. K.,
Friis, R. R.,
Schoenenberger, C. A.,
Doppler, W.,
and Groner, B.
(1988)
EMBO J.
7,
2089-2095[Medline]
[Order article via Infotrieve]
15.
Krylov, D.,
Kasai, K.,
Echlin, D. R.,
Taparowsky, E. J.,
Arnheiter, H.,
and Vinson, C.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
12274-12279 16.
Giguere, V.,
Tini, M.,
Flock, G.,
Ong, E.,
Evans, R. M.,
and Otulakowski, G.
(1994)
Genes Dev.
8,
538-553 17.
Dear, T. N.,
Hainzl, T.,
Follo, M.,
Nehls, M.,
Wilmore, H.,
Matena, K.,
and Boehm, T.
(1997)
Oncogene
14,
891-898[CrossRef][Medline]
[Order article via Infotrieve]
18.
Tietze, K.,
Oellers, N.,
and Knust, E.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
6152-6156 19.
Oellers, N.,
Dehio, M.,
and Knust, E.
(1994)
Mol. Gen. Genet.
244,
465-473[CrossRef][Medline]
[Order article via Infotrieve]
20.
Dang, C. V.,
Dolde, C.,
Gillison, M. L.,
and Kato, G. J.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
599-602 21.
Jennings, B. H.,
Tyler, D. M.,
and Bray, S. J.
(1999)
Mol. Cell. Biol.
19,
4600-4610 22.
Yun, Z.,
Maecker, H. L.,
Johnson, R. S.,
and Giaccia, A. J.
(2002)
Dev. Cell
2,
331-341[CrossRef][Medline]
[Order article via Infotrieve]
23.
Zawel, L., Yu, J.,
Torrance, C. J.,
Markowitz, S.,
Kinzler, K. W.,
Vogelstein, B.,
and Zhou, S.
(2002)
Proc. Natl. Acad. Sci. U. S. A.
99,
2848-2853 24.
Dhar, M.,
and Taneja, R.
(2001)
Oncogene
20,
4750-4756[CrossRef][Medline]
[Order article via Infotrieve]
25.
Teramoto, M.,
Nakamasu, K.,
Noshiro, M.,
Matsuda, Y.,
Gotoh, O.,
Shen, M.,
Tsutsumi, S.,
Kawamoto, T.,
Iwamoto, Y.,
and Kato, Y.
(2001)
J. Biochem. (Tokyo)
129,
391-396
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
Y. Qian and X. Chen ID1, Inhibitor of Differentiation/DNA Binding, Is an Effector of the p53-dependent DNA Damage Response Pathway J. Biol. Chem., August 15, 2008; 283(33): 22410 - 22416. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Jiang, F. Tian, Y. Du, N. G. Copeland, N. A. Jenkins, L. Tessarollo, X. Wu, H. Pan, X.-Z. Hu, K. Xu, et al. BHLHB2 Controls Bdnf Promoter 4 Activity and Neuronal Excitability J. Neurosci., January 30, 2008; 28(5): 1118 - 1130. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Rehli{section}, S. Sulzbacher, S. Pape, T. Ravasi, C. A. Wells, S. Heinz, L. Sollner, C. El Chartouni, S. W. Krause, E. Steingrimsson, et al. Transcription Factor Tfec Contributes to the IL-4-Inducible Expression of a Small Group of Genes in Mouse Macrophages Including the Granulocyte Colony-Stimulating Factor Receptor J. Immunol., June 1, 2005; 174(11): 7111 - 7122. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. St-Pierre, X. Liu, L.-C. T. Kha, X. Zhu, O. Ryan, Z. Jiang, and E. Zacksenhaus Conserved and specific functions of mammalian ssu72 Nucleic Acids Res., January 19, 2005; 33(2): 464 - 477. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Azmi, A. Ozog, and R. Taneja Sharp-1/DEC2 Inhibits Skeletal Muscle Differentiation through Repression of Myogenic Transcription Factors J. Biol. Chem., December 10, 2004; 279(50): 52643 - 52652. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Spin, S. Nallamshetty, R. Tabibiazar, E. A. Ashley, J. Y. King, M. Chen, P. S. Tsao, and T. Quertermous Transcriptional profiling of in vitro smooth muscle cell differentiation identifies specific patterns of gene and pathway activation Physiol Genomics, November 17, 2004; 19(3): 292 - 302. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Krappmann, E. Wegener, Y. Sunami, M. Esen, A. Thiel, B. Mordmuller, and C. Scheidereit The I{kappa}B Kinase Complex and NF-{kappa}B Act as Master Regulators of Lipopolysaccharide-Induced Gene Expression and Control Subordinate Activation of AP-1 Mol. Cell. Biol., July 15, 2004; 24(14): 6488 - 6500. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Boverhof, K. C. Fertuck, L. D. Burgoon, J. E. Eckel, C. Gennings, and T. R. Zacharewski Temporal- and dose-dependent hepatic gene expression changes in immature ovariectomized mice following exposure to ethynyl estradiol Carcinogenesis, July 1, 2004; 25(7): 1277 - 1291. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Gurok, C. Steinhoff, B. Lipkowitz, H.-H. Ropers, C. Scharff, and U. A. Nuber Gene Expression Changes in the Course of Neural Progenitor Cell Differentiation J. Neurosci., June 30, 2004; 24(26): 5982 - 6002. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. B. Hough and J. Piatigorsky Preferential Transcription of Rabbit Aldh1a1 in the Cornea: Implication of Hypoxia-Related Pathways Mol. Cell. Biol., February 1, 2004; 24(3): 1324 - 1340. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Coulet, S. Nadaud, M. Agrapart, and F. Soubrier Identification of Hypoxia-response Element in the Human Endothelial Nitric-oxide Synthase Gene Promoter J. Biol. Chem., November 21, 2003; 278(47): 46230 - 46240. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Li, M. Xie, X. Song, S. Gragen, K. Sachdeva, Y. Wan, and B. Yan DEC1 Negatively Regulates the Expression of DEC2 through Binding to the E-box in the Proximal Promoter J. Biol. Chem., May 2, 2003; 278(19): 16899 - 16907. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||